Located within the marvelous New Forest Park in England, the Wessex Institute of Technology is an educational and research organization serving the international scientific community. The aim of the Wessex Institute of Technology is to develop a series of new innovative ways that facilitate the exchange of vital information between academics and professional users to promote legitimate business environments. There are many career opportunities available at Wessex Institute for individuals who wish to work with world-class prestigious contacts organised by a devoted team within the institute and its associate companies.
The Institute provides Graduate Programmes, Specialist Research, an International Conference Programme, a Publishing Arm, Software Services and access to an American Office based in Boston. The Wessex Institute of Technology combines advanced research with industrial needs to provide solutions and expertise on information through professional work all while maintaining an international reputation in research quality.
Cancer is a hard pill to swallow. For both patients and loved ones, the reality of the complex illness is frightening. Over the last decade, we have seen a rise in cancer patients both young and old, and of all ethnicities. For years, chemotherapy has been the most commonly used cancer treatment procedure. While several patients choose this option, chemotherapy introduces several toxic side effects to the human body. Being educated about the effects of chemotherapy is important, and having other options can possibly help improve both the quality and longevity of each patient’s life.
Seattle Genetics is a well known biotechnology company committed to delivering innovative alternative cancer treatment solutions to patients all over the world. They are considered world leaders in antibody-based cancer treatment therapies and ADCs (antibody-drug conjugates). With ADC therapy, cancer cells are targeted and executed with the help of cell-killing agents without the use of radiation. The new innovative treatment therapy is designed to avoid non cancerous cells, prompting a decrease in toxic side effects and tumor growth.
ADCETRIS is the first in a series of new ADC treatment therapies from Seattle Genetics. ADCETRIS targets the protein CD30, which is present is Hodgkin lymphoma and systemic anaplastic large cell lymphoma. In a clinical trial conducted in 2010, Seattle Genetics concluded that nearly 95% of patients experienced tumor reduction activity, and nearly half of patients achieved either complete or partial remission. Overall, patients who choose ADCETRIS for treatment saw a significant improvement in symptoms related to Hodgkin lymphoma.
Clay Siegall helped launch Seattle Genetics in 1998 and currently serves as President, Chairman and CEO of the company. After earning his Ph.D. in Genetics at George Washington University, Siegall began to build his professional reputation and establish his name in the pharmaceutical industry. He has extensive training and experience in science in relation to biotechnology and cancer treatment therapies. It is through his guidance that Seattle Genetics landed its current position at the top for cancer treatment therapies.